Selecta Biosciences

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease –

Selecta Biosciences Announces Merger with Cartesian Therapeutics

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum AB (publ.) (Sobi). As of November 6, 2023, Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212. SEL-212, a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for the treatment of chronic refractory gout. A Biologics License Application (BLA) submission for SEL-212 remains on track for the first half of 2024.

Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi

Selecta Biosciences, Inc. (SELB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.06 per share a year ago.

Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates

– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 –

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

- Phase 3 DISSOLVE I and DISSOLVE II studies both met their primary efficacy endpoints, with SEL-212-treated patients demonstrating statistically significant higher response rates compared to placebo -

Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology

Selecta Biosciences, Inc. (NASDAQ:SELB ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Blaine Davis - CFO Carsten Brunn - CEO, President & Director Peter Traber - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Securities Kristen Kluska - Cantor Fitzgerald John Newman - Canaccord Genuity Dipesh Patel - H.C. Wainwright & Co. Uy Ear - Mizuho Securities Gil Blum - Needham & Company Operator Good morning, and thank you for joining the Selecta Biosciences First Quarter 2023 Earnings Call.

Selecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call Transcript

Selecta Biosciences, Inc. (SELB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.07 per share a year ago.

Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates

- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout; BLA filing expected in 1H 2024 - - Selecta to host conference call today at 8:30 AM ET - WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today  announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update.

Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

BlackBerry

Terran Orbital Corp

Mereo Biopharma Group Plc - ADR

Penny stocks to watch this week. The post 4 Hot Penny Stocks To Watch With News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks To Watch With News This Week

--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II --75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of therapy with no infusion reactions or new safety signals --Favorable safety profile with 3.4% of patients with infusion reactions at high dose WATERTOWN, Mass. and STOCKHOLM , March 21, 2023 /PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials to determine safety and efficacy of two different dose levels of SEL-212 in adult patients with chronic refractory gout.

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II --75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of therapy with no infusion reactions or new safety signals --Favorable safety profile with 3.4% of patients with infusion reactions at high dose --Selecta will host a conference call and webcast today at 8:30 AM ET / 2:30 PM CET

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint

Selecta Biosciences, Inc. (NASDAQ:SELB ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Blaine Davis - Chief Financial Officer Carsten Brunn - President, Chief Executive Officer & Director Peter Traber - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Securities Kristen Kluska - Cantor Fitzgerald John Newman - Canaccord Genuity Yun Zhong - BTIG Gil Blum - Needham & Company Tiffany Marchell - William Blair Boobalan Pachaiyappan - H.C. Wainwright Uy Ear - Mizuho Operator Good morning, and welcome to the Selecta Bio Fourth Quarter 2022 Earnings Release Conference Call.

Selecta Biosciences, Inc. (SELB) Q4 2022 Earnings Call Transcript

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 25% and 32.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates

- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 -

Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2022 and provide a business update.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update

Amneal Pharmaceuticals

Atossa Genetics

Troika Media Group

Penny stocks under $3 to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Stocks Under $3 To Watch This Week

Chimerix

Genfit - ADR

Harmony Biosciences Holdings

iTeos Therapeutics, Inc.

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.

The 7 Best Biotech Stocks to Buy for February 2023

WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that Company's Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.

Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference

- Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 -

Selecta Biosciences Provides Business Update and Outlook for 2023

Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease Selecta to receive a $10M upfront payment and eligible to receive up to $340M for certain additional development and commercial milestones plus royalties on commercial sales WATERTOWN, Mass. and TOKYO , Jan. 9, 2023 /PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB, President and CEO: Carsten Brunn, Ph.D.

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease

– IgA protease candidate in combination with ImmTOR further enhances pipeline –

Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program

I covered SELB twice. The gout phase 3 trial has certain challenges.

News for Selecta Biosciences Stock (SELB)